We are live on ! Find out more

Jade Biosciences

JBIO

Market cap $927M

14.57 USD

+0.64

4.59%

At close Updated Nov 3, 4:00 PM EST

Pre-market

After hours

15.40

+0.83

5.7%

1 day

4.59%

5 days

-0.14%

1 month

3.55%

3 months

-23.92%

6 months

-40.58%

Year to date

2.9%

1 year

53.85%

5 years

-97.48%

10 years

-98.18%

About: Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Employees: 55

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 87.5%

Negative 0%

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat: Tuesday, November 10, 2026 at 3:00 p.m. ETLocation: Boston, MA Stifel Healthcare Conference Fireside Chat: Wednesday, November 11, 2026 at 10:00 a.m.

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026 JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing study of JADE101 in IgA nephropathy; interim data now expected in the second quarter of 2027 SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that three posters related to JADE101, a novel, ultra-high affinity and half-life extended investigational anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody in development for the treatment of immunoglobulin A nephropathy (IgAN), will be presented at the American Society of Nephrology (ASN) Kidney Week 2026, being held in Denver, Colorado from October 21-25, 2026. The presentations highlight both the scientific foundation and continued clinical advancement of the JADE101 program in IgAN, including the planned acceleration of the EVERGREEN Phase 3 clinical trial, with initiation now expected in the fourth quarter of 2026.

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cells Following subcutaneous administration in non-human primates, JADE301 was effectively half-life extended with an approximately 25-day half-life and predictable distribution into muscle JADE301 was well tolerated in non-human primates at all evaluated subcutaneous doses Phase 1 healthy volunteer trial expected to begin in the fourth quarter of 2026; interim data anticipated in the second half of 2027 Company to host conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, Sept.

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Tuesday, September 8 at 3:45 p.m.

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences: Duration Is The Real Product

Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor), both engineered for extended-interval dosing to differentiate in validated autoimmune markets.

Jade Biosciences: Duration Is The Real Product

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027 Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027 Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027 JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 2027 Cash, cash equivalents, and investments of $461 million as of June 30, 2026 expected to provide runway into the fourth quarter of 2028 SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the second quarter ending June 30, 2026, and provided a corporate update. “This was an important period for Jade as we reported positive interim Phase 1 data for JADE101 that exceeded our expectations across biomarker activity and durability, with a favorable safety profile, strengthening our conviction to rapidly advance the compound to deliver a potentially best-in-class profile in IgA nephropathy,” said Tom Frohlich, Chief Executive Officer of Jade Biosciences.

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026.

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $172.5 million. All of the shares of common stock sold in the public offering were sold by Jade.

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

See News Rankings

Price charts implemented using Lightweight Charts™